Search clinical trials for: ACT-389949 (Group C2 dose to be selected)

Total 8 results

Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

Healthy Subjects

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

France
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Altheos, Inc.

Unknown

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Memorial Sloan Kettering Cancer Center

Completed

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

Liver Cancer

United States
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Puerto Rico
AO GENERIUM

Withdrawn

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

Hereditary Angioedema

Russian Federation
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Neuroblastoma

United States

3

Subscribe